Seeking Alpha

J&J drug for rare cancer performs well in Phase II study

Johnson & Johnson's (JNJ) Siltuximab drug reduced tumors in a Phase II trial of 79 patients with Castleman disease, a very rare condition that is characterized by enlarged lymph nodes and for which there are no approved therapies.

A third of the subjects who received siltuximab responded vs none who were given a placebo. A quarter had all symptoms of the disease completely resolved for a median period of 1.3 years.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs